Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Santen Pharmaceutical Co., Ltd. (4536.T)
Osaka, JP
Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addressing a variety of eye conditions. Its pipeline for glaucoma and ocular hypertension includes several key assets: DE-111, currently in Phase III clinical trials; DE-117, available for sale in Japan; DE-126, progressing through Phase IIb trials; DE-128, which is on the market in Europe and undergoing Phase II/III trials in the United States; and DE-130A, also in Phase III development. Beyond glaucoma, Santen's offerings extend to other ocular ailments. It provides DE-114A for allergic conjunctivitis and DE-076C for vernal keratoconjunctivitis. Furthermore, DE-109 is in Phase III clinical trials for the treatment of uveitis. The company is also active in addressing myopia with DE-127, currently in Phase II/III trials in Japan and Phase III in other Asian markets, alongside STN1013400, which is in Phase I trials. For dry eye, Santen offers DE-089C, which has successfully concluded its Phase III clinical trials. In addition to its prescription portfolio, the company produces and sells various over-the-counter (OTC) pharmaceutical products. Founded in 1890 under the name Santendo Pharmaceutical Co., Ltd., the company rebranded to its current name, Santen Pharmaceutical Co., Ltd., in 1958. It is headquartered in Osaka, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +16.23% | +11.69% | +0.50% | +5.52% | +17.44% | +10.27% | +27.46% | +47.20% | +24.23% | +14.29% | +290.32% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 3 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%-2.8% Q1'26: +4.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+9.8% Q1'26: +85.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+11.0% Q1'26: +23.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+15.5% Q1'26: +21.1% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+16.6% ★ Q1'26: +25.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-6.1% ★ Q1'26: -4.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 9 Rev. Ana. 9 EPS Ana. |
Mar 2027 5 Rev. Ana. 6 EPS Ana. |
Mar 2028 8 Rev. Ana. 8 EPS Ana. |
Mar 2029 4 Rev. Ana. 4 EPS Ana. |
Mar 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
161.83B
est: 160.68B (+0.7%)
|
195.29B
est: 196.76B (-0.7%)
|
199.10B
est: 200.94B (-0.9%)
|
224.94B
est: 223.04B (+0.9%)
|
234.03B
est: 234.60B (-0.2%)
|
241.56B
est: 243.22B (-0.7%)
|
249.61B
est: 243.04B (+2.7%)
|
266.26B
est: 264.20B (+0.8%)
|
279.04B
est: 272.60B (+2.4%)
|
301.97B
est: 304.35B (-0.8%)
|
300.00B
est: 298.63B (+0.5%)
|
290.28B
281.55B – 296.43B
-2.8% YoY
|
299.52B
294.18B – 306.83B
+3.2% YoY
|
311.18B
267.93B – 350.93B
+3.9% YoY
|
330.60B
322.66B – 338.54B
+6.2% YoY
|
356.25B
328.30B – 383.37B
+7.8% YoY
|
| EBITDA |
41.95B
est: 25.47B (+64.7%)
|
45.84B
est: 31.19B (+47.0%)
|
43.18B
est: 31.85B (+35.6%)
|
49.53B
est: 35.36B (+40.1%)
|
52.21B
est: 37.19B (+40.4%)
|
56.70B
est: 38.56B (+47.0%)
|
54.99B
est: 38.53B (+42.7%)
|
53.03B
est: 41.88B (+26.6%)
|
49.26B
est: 43.21B (+14.0%)
|
70.08B
est: 87.76B (-20.1%)
|
74.18B
est: 86.11B (-13.9%)
|
83.71B
81.19B – 85.48B
-2.8% YoY
|
86.37B
84.83B – 88.48B
+3.2% YoY
|
89.73B
77.26B – 101.20B
+3.9% YoY
|
95.34B
93.05B – 97.62B
+6.2% YoY
|
102.73B
94.67B – 110.55B
+7.8% YoY
|
| EBIT |
35.00B
est: 15.26B (+129.3%)
|
36.50B
est: 18.69B (+95.3%)
|
33.30B
est: 19.09B (+74.5%)
|
38.64B
est: 21.19B (+82.4%)
|
41.24B
est: 22.28B (+85.1%)
|
40.13B
est: 23.10B (+73.7%)
|
37.07B
est: 23.09B (+60.6%)
|
35.98B
est: 25.10B (+43.4%)
|
32.02B
est: 25.89B (+23.6%)
|
51.90B
est: 73.42B (-29.3%)
|
56.23B
est: 72.04B (-21.9%)
|
70.03B
67.92B – 71.51B
-2.8% YoY
|
72.26B
70.97B – 74.02B
+3.2% YoY
|
75.07B
64.64B – 84.66B
+3.9% YoY
|
79.75B
77.84B – 81.67B
+6.2% YoY
|
85.94B
79.20B – 92.48B
+7.8% YoY
|
| Net Income |
24.03B
est: 18.04B (+33.2%)
|
53.37B
est: 46.18B (+15.6%)
|
21.72B
est: 22.73B (-4.4%)
|
35.25B
est: 26.57B (+32.6%)
|
31.95B
est: 27.43B (+16.5%)
|
23.62B
est: 20.38B (+15.9%)
|
9.31B
est: 18.98B (-51.0%)
|
27.22B
est: 25.47B (+6.9%)
|
-14.95B
est: -12.48B (-19.8%)
|
26.64B
est: 26.85B (-0.8%)
|
36.26B
est: 31.49B (+15.1%)
|
34.87B
32.51B – 37.24B
+10.7% YoY
|
39.63B
36.96B – 42.31B
+13.7% YoY
|
38.88B
36.04B – 53.50B
-1.9% YoY
|
42.33B
40.44B – 60.69B
+8.8% YoY
|
48.59B
43.63B – 53.39B
+14.8% YoY
|
| SGA |
48.07B
est: 50.24B (-4.3%)
|
58.38B
est: 61.52B (-5.1%)
|
60.39B
est: 62.82B (-3.9%)
|
67.34B
est: 69.73B (-3.4%)
|
69.80B
est: 73.35B (-4.8%)
|
71.90B
est: 76.04B (-5.5%)
|
79.55B
est: 75.99B (+4.7%)
|
84.50B
est: 82.60B (+2.3%)
|
96.26B
est: 85.23B (+12.9%)
|
87.27B
est: 94.25B (-7.4%)
|
83.51B
est: 92.48B (-9.7%)
|
89.90B
87.19B – 91.80B
-2.8% YoY
|
92.76B
91.10B – 95.02B
+3.2% YoY
|
96.37B
82.97B – 108.68B
+3.9% YoY
|
102.38B
99.92B – 104.84B
+6.2% YoY
|
110.32B
101.67B – 118.72B
+7.8% YoY
|
| EPS |
58.18
est: 51.60 (+12.8%)
|
128.99
est: 132.07 (-2.3%)
|
52.96
est: 64.99 (-18.5%)
|
86.73
est: 75.99 (+14.1%)
|
78.67
est: 78.44 (+0.3%)
|
59.16
est: 58.28 (+1.5%)
|
23.30
est: 54.29 (-57.1%)
|
68.07
est: 72.83 (-6.5%)
|
-38.60
est: -36.70 (-5.2%)
|
72.59
est: 73.88 (-1.7%)
|
103.98
est: 99.17 (+4.9%)
|
98.75
92.96 – 106.48
-0.4% YoY
|
113.01
105.68 – 120.98
+14.4% YoY
|
127.16
103.07 – 153.00
+12.5% YoY
|
142.36
115.65 – 173.54
+12.0% YoY
|
138.94
124.77 – 152.69
-2.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | OneAscent International Equity ETF OAIM | 1.51% | 5.57M | 0.95% |
| 2 | Matthews Japan Active ETF JPAN JPAN | 1.07% | 108.1K | 0.79% |
| 3 | iShares Ageing Population UCITS ETF AGED.L | 0.36% | 3.22M | 0.40% |
| 4 | JPMorgan Diversified Return International Equity ETF JPIN | 0.31% | 1.13M | 0.37% |
| 5 | iShares International Equity Factor ETF INTF | 0.31% | 10.84M | 0.16% |
| 6 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.29% | 1.64M | 0.58% |
| 7 | iShares MSCI Japan Small-Cap ETF SCJ | 0.28% | 731.6K | 0.50% |
| 8 | Hartford Multifactor Developed Markets (ex-US) ETF RODM | 0.28% | 4.44M | 0.29% |
| 9 | Xtrackers FTSE Developed ex US Multifactor ETF DEEF | 0.17% | 93.6K | 0.24% |
| 10 | Avantis International Small Cap Equity ETF AVDS | 0.15% | 460.3K | 0.30% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Takeshi Ito | President, Chief Executive Officer & Representative Director | 172M | male |
| Kaori Itagaki | General Manager of Investor Relations Group | — | female |
| Kazuo Koshiji | Chief Financial Officer & Corporate Officer | — | male |
| Kenji Morishima | Corporate Officer & Head of China Product Development Department | — | male |
| Mika Masunari | Corporate Officer, General Counsel, Chief Risk Officer & Chief Compliance Officer | — | female |
| Rie Nakajima | Chief Operating Officer, Corporate Officer & Director | — | female |
| Shinichi Teramachi | Corporation Officer, Head of Sales and Head of Japan Sales & Marketing | — | male |
| Takahiro Morita | Global Head of Core Principle & Sustainability and Corporate Officer | — | male |
| Daisuke Nakata | Chief Digital & Information Officer | — | male |
| Yoko Saiki | Corporate Officer & Chief Human Resources Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4536.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
